Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Current Investments: 2014-2025

Historic Cash & Current Investments for AC Immune (ACIU) over the last 12 years, with Sep 2025 value amounting to $135.6 million.

  • AC Immune's Cash & Current Investments fell 25.60% to $135.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $451.3 million, marking a year-over-year decrease of 26.28%. This contributed to the annual value of $135.6 million for FY2025, which is N/A change from last year.
  • According to the latest figures from FY2025, AC Immune's Cash & Current Investments is $135.6 million, which was up 71,676.80% from $188,909 recorded in FY2024.
  • AC Immune's 5-year Cash & Current Investments high stood at $216.9 million for FY2021, and its period low was $116,172 during FY2023.
  • Its 3-year average for Cash & Current Investments is $45.3 million, with a median of $188,909 in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 99.91% in 2023, then spiked by 62.61% in 2024.
  • Yearly analysis of 5 years shows AC Immune's Cash & Current Investments stood at $216.9 million in 2021, then tumbled by 41.34% to $127.2 million in 2022, then plummeted by 99.91% to $116,172 in 2023, then soared by 62.61% to $188,909 in 2024, then reached $135.6 million in 2025.